These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 17699579

  • 1. Ribavirin reveals a lethal threshold of allowable mutation frequency for Hantaan virus.
    Chung DH, Sun Y, Parker WB, Arterburn JB, Bartolucci A, Jonsson CB.
    J Virol; 2007 Nov; 81(21):11722-9. PubMed ID: 17699579
    [Abstract] [Full Text] [Related]

  • 2. Activity of ribavirin against Hantaan virus correlates with production of ribavirin-5'-triphosphate, not with inhibition of IMP dehydrogenase.
    Sun Y, Chung DH, Chu YK, Jonsson CB, Parker WB.
    Antimicrob Agents Chemother; 2007 Jan; 51(1):84-8. PubMed ID: 17060520
    [Abstract] [Full Text] [Related]

  • 3. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
    Lee HJ, Pawlak K, Nguyen BT, Robins RK, Sadée W.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
    [Abstract] [Full Text] [Related]

  • 4. The murine model for Hantaan virus-induced lethal disease shows two distinct paths in viral evolutionary trajectory with and without ribavirin treatment.
    Chung DH, Västermark Å, Camp JV, McAllister R, Remold SK, Chu YK, Bruder C, Jonsson CB.
    J Virol; 2013 Oct; 87(20):10997-1007. PubMed ID: 23903835
    [Abstract] [Full Text] [Related]

  • 5. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase.
    Leyssen P, Balzarini J, De Clercq E, Neyts J.
    J Virol; 2005 Feb; 79(3):1943-7. PubMed ID: 15650220
    [Abstract] [Full Text] [Related]

  • 6. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus.
    Ölschläger S, Neyts J, Günther S.
    Antiviral Res; 2011 Aug; 91(2):89-93. PubMed ID: 21616094
    [Abstract] [Full Text] [Related]

  • 7. Ribavirin causes error catastrophe during Hantaan virus replication.
    Severson WE, Schmaljohn CS, Javadian A, Jonsson CB.
    J Virol; 2003 Jan; 77(1):481-8. PubMed ID: 12477853
    [Abstract] [Full Text] [Related]

  • 8. Sindbis virus mutants resistant to mycophenolic acid and ribavirin.
    Scheidel LM, Durbin RK, Stollar V.
    Virology; 1987 May; 158(1):1-7. PubMed ID: 3033882
    [Abstract] [Full Text] [Related]

  • 9. In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1.
    Borroto-Esoda K, Myrick F, Feng J, Jeffrey J, Furman P.
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4387-94. PubMed ID: 15504868
    [Abstract] [Full Text] [Related]

  • 10. Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro.
    Smee DF, Bray M, Huggins JW.
    Antivir Chem Chemother; 2001 Nov; 12(6):327-35. PubMed ID: 12018677
    [Abstract] [Full Text] [Related]

  • 11. The importance of IMP dehydrogenase inhibition in the broad spectrum antiviral activity of ribavirin and selenazofurin.
    Robins RK, Revankar GR, McKernan PA, Murray BK, Kirsi JJ, North JA.
    Adv Enzyme Regul; 1985 Nov; 24():29-43. PubMed ID: 2872781
    [Abstract] [Full Text] [Related]

  • 12. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus.
    Paragas J, Whitehouse CA, Endy TP, Bray M.
    Antiviral Res; 2004 Apr; 62(1):21-5. PubMed ID: 15026198
    [Abstract] [Full Text] [Related]

  • 13. The anti-yellow fever virus activity of ribavirin is independent of error-prone replication.
    Leyssen P, De Clercq E, Neyts J.
    Mol Pharmacol; 2006 Apr; 69(4):1461-7. PubMed ID: 16421290
    [Abstract] [Full Text] [Related]

  • 14. Synthesis of 1-beta-D-ribofuranosyl-3-ethynyl-[1,2,4]triazole and its in vitro and in vivo efficacy against Hantavirus.
    Chung DH, Kumarapperuma SC, Sun Y, Li Q, Chu YK, Arterburn JB, Parker WB, Smith J, Spik K, Ramanathan HN, Schmaljohn CS, Jonsson CB.
    Antiviral Res; 2008 Jul; 79(1):19-27. PubMed ID: 18394724
    [Abstract] [Full Text] [Related]

  • 15. Broad-spectrum synergistic antiviral activity of selenazofurin and ribavirin.
    Kirsi JJ, McKernan PA, Burns NJ, North JA, Murray BK, Robins RK.
    Antimicrob Agents Chemother; 1984 Oct; 26(4):466-75. PubMed ID: 6517540
    [Abstract] [Full Text] [Related]

  • 16. Inhibitors of the IMPDH enzyme as potential anti-bovine viral diarrhoea virus agents.
    Stuyver LJ, Lostia S, Patterson SE, Clark JL, Watanabe KA, Otto MJ, Pankiewicz KW.
    Antivir Chem Chemother; 2002 Nov; 13(6):345-52. PubMed ID: 12718406
    [Abstract] [Full Text] [Related]

  • 17. Antiviral efficacy of EICAR against canine distemper virus (CDV) in vitro.
    Dal Pozzo F, Galligioni V, Vaccari F, Gallina L, Battilani M, Scagliarini A.
    Res Vet Sci; 2010 Apr; 88(2):339-44. PubMed ID: 19781726
    [Abstract] [Full Text] [Related]

  • 18. Eukaryotic initiation factor 5B: a new player for the anti-hepatitis C virus effect of ribavirin?
    Galmozzi E, Aghemo A, Colombo M.
    Med Hypotheses; 2012 Oct; 79(4):471-3. PubMed ID: 22824093
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of dengue virus replication by mycophenolic acid and ribavirin.
    Takhampunya R, Ubol S, Houng HS, Cameron CE, Padmanabhan R.
    J Gen Virol; 2006 Jul; 87(Pt 7):1947-1952. PubMed ID: 16760396
    [Abstract] [Full Text] [Related]

  • 20. Error-prone replication of West Nile virus caused by ribavirin.
    Day CW, Smee DF, Julander JG, Yamshchikov VF, Sidwell RW, Morrey JD.
    Antiviral Res; 2005 Jul; 67(1):38-45. PubMed ID: 15919121
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.